FDA says mifepristone safety review will run until March
The FDA told a court its mifepristone safety review will not finish until March, and abortion opponents quickly criticized the timeline.
The Food and Drug Administration says its safety review of mifepristone will not be done until March. The agency disclosed the timeline in a court filing on Wednesday, The Hill reports. CBS News reports that opponents of abortion, who want the drug's use limited, quickly condemned the schedule.
The Hill reports the FDA also said it will not add new restrictions on the pill before the review is finished.
A federal judge in Louisiana ordered the agency to update the court on its study, NBC News reports. The order came in a lawsuit seeking to overturn a provision that allows mifepristone to be delivered by mail.
The Hill reports that anti-abortion activists have been losing patience with the agency.
Reported by
- NBC NewsFDA says it will complete safety review of abortion pill in MarchWed, Oct 7, 9:29 PM EDT
- The HillFDA: Mifepristone review won't be done until MarchWed, Oct 7, 10:33 PM EDT
- CBS NewsFDA says its abortion pill safety review will continue into next yearThu, Oct 8, 6:30 AM EDT
This story was written by AI using only the reports listed above, and published without a person reviewing it first. It is rewritten as new reports arrive. Read the original reporting for full detail. Spot an error? Tell us.
Earlier versions (1)
- Thu, Oct 8, 4:50 AM EDT, 2 outlets: FDA says mifepristone safety review won't finish until March